WILMINGTON, DE — Incyte will present an expansive slate of research at the 2025 American Society of Hematology (ASH) Annual Meeting, highlighting new data across its myeloproliferative neoplasm (MPN), graft-versus-host disease (GVHD) and hematologic oncology programs. The lineup includes three presentations on INCA033989, the company’s first-in-class monoclonal antibody designed to target mutant calreticulin (mutCALR), a driver of multiple MPNs.
The company will unveil updated Phase 1 results of INCA033989 as monotherapy in myelofibrosis patients who are refractory or intolerant to ruxolitinib, along with combination data evaluating the antibody alongside ruxolitinib in individuals with suboptimal responses. Additional data will include emerging safety and efficacy findings in essential thrombocythemia, underscoring the candidate’s potential as a disease-modifying agent across MPN subtypes.
Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte, said the breadth of presentations demonstrates the momentum of the company’s oncology portfolio. He noted that the mutCALR program, along with updated findings for axatilimab in GVHD and tafasitamab in follicular lymphoma, showcases the company’s advancing pipeline and its push toward next-generation therapies.
Beyond mutCALR, Incyte will showcase interim safety data for axatilimab (Niktimvo™) in combination with ruxolitinib for GVHD, updated BET inhibitor findings for INCB057643, and multiple studies evaluating ruxolitinib (Jakafi®) across polycythemia vera, myelofibrosis, and chronic GVHD populations. Additional presentations will cover development programs targeting ALK2, JAK2V617F and extended-release ruxolitinib formulations.
In total, the company has more than 50 abstracts accepted at this year’s meeting, spanning basic science, translational research, early-stage trials and real-world evidence.
Incyte will host an investor webcast on December 7 to discuss the mutCALR oral presentation and broader program updates. The event will be streamed through the company’s investor relations website and archived for 30 days.
The ASH Annual Meeting will take place December 6–9 in Orlando, providing a global stage for new hematology research, therapeutic innovation and clinical development updates.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.